Article
Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABA(A)-receptor complexes.
PloS one - 1 Jan 2014
Jensen Henrik Sindal, Nichol Kathryn, Lee Deborah, Ebert Bjarke
Abstract excerpt
Clobazam (CLB), a 1,5-benzodiazepine (BZD), was FDA-approved in October 2011 for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older. BZDs exert various CNS effects through allosteric modulation of GABAA receptors. The structurally distinct, 1,4-BZD clonazepam (CLN) is also approved to treat LGS. The precise mechanisms of action and clinical efficacy of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.